12:00 AM
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tofacitinib: Additional Phase III data

Additional data from the double-blind, international Phase III ORAL Standard (1064) trial in 717 patients who had an inadequate response to methotrexate showed that twice-daily 5 and 10 mg oral tofacitinib led to ACR20 response rates at 6 months of 51.5% and 52.6%, respectively, vs. 28.3% for placebo (p<0.001 for both). Low- and high-dose tofacitinib also improved HAQ-DI scores from baseline to 3 months by 0.55 and 0.61 points, respectively, vs. 0.24 points for placebo (p<0.001 for both). Furthermore, 6.2% and 12.5% of patients receiving low- and high-dose tofacitinib, respectively, achieved a DAS28 score of <2.6 at 6 months vs. 1.1%...

Read the full 494 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >